Amendments

In the Claims:

Claims 1-35 (canceled).

36. (previously presented) A method for treating a condition, comprising administering to a subject in need thereof an effective amount of a composition consisting of (a) pharmaceutically acceptable carrier and (b) active agent consisting of (i) hyperforin or (ii) hyperforin and hypericin, wherein said condition is selected from the group consisting of an inflammatory skin condition, a precancerous condition, a geriatric skin condition, and a microbial skin infection.

37. (previously presented) The method according to claim 36, wherein the condition is eczema.

38. (currently amended) The method ~~according to claim 36~~ for treating a condition comprising administering to a subject in need thereof an effective amount of a composition consisting of (a) pharmaceutically acceptable carrier and (b) active agent consisting of (i) hyperforin or (ii) hyperforin and hypericin, wherein said condition is selected from the group consisting of exsiccation eczemas, hyperkeratotic hand and foot eczemas, contact eczemas, atopic dermatitis, neurodermatitis, lichen simplex, prurigo simplex, lymphomas, leukemia, an epithelial pre-cancerous condition, tumor metastases, and epithelial tumor.

39. (previously presented) The method according to claim 36, wherein said subject is a mammal.

40. (previously presented) The method according to claim 36, wherein said composition is in the form of a topical ointment and said effective amount consists of at least 15 μg hyperforin per ml of the composition.

41. (previously presented) The method according to claim 36, wherein said composition is in the form of a topical ointment and said effective amount is 0.02-20 mg hyperforin per ml of the composition.

42. (previously presented) The method according to claim 41 wherein said effective amount is 1-20 mg hyperforin per ml of the composition.

43. (previously presented) The method according to claim 42 wherein said effective amount is 10 mg hyperforin per ml of the composition.

44. (previously presented) The method according to claim 36, wherein said effective amount is at least 15 μg hypericin per ml of the composition.

45. (previously presented) The method according to claim 36, wherein said effective amount of hypericin is 20-150 μg hypericin per ml of the composition.

Claims 46-55 (canceled)

56. (previously presented) The method of claim ~~46~~ 36, wherein said hyperforin is at least 90% pure.

57. (new claim) The method of claim 38 wherein said condition is lymphoma or leukemia.